Lynn Sage Breast Cancer Symposium | Conference

Immunotherapy for Breast Cancer: What's New and What's on the Horizon?

October 7th 2019

Immunotherapy may finally be taking center stage in breast cancer, although much work remains to be done.

Earlier Diagnosis and Treatment Are Next Steps in TNBC Paradigm

October 7th 2019

There is an unprecedented array of therapeutic options for patients with triple-negative breast cancer, with more approaches on the horizon.

Dr. Osborne on Evaluating HER2 Positivity in Breast Cancer

October 7th 2019

C. Kent Osborne, MD, discusses the important take home message for physicians treating patients with HER2-positive breast cancer. Osborne says the role of HER2-positivity is complicated.

Rugo Highlights Latest Advances in TNBC Treatment

October 6th 2019

Hope S. Rugo, MD, discusses the latest advancements in the treatment landscape for patients with TNBC and highlights some data from clinical trials presented at the 2019 ESMO Congress.

Dr. Barrio on Neoadjuvant Chemo to De-Escalate Axillary Node Dissection in Breast Cancer

October 6th 2019

Andrea V. Barrio, MD, FACS, discusses how the use of neoadjuvant chemotherapy can help de-escalate axillary node dissection in select patients with breast cancer. Dissection can be a morbid procedure with longterm risks of lymphoma, impacting the quality of life for many patients.

Use of Neoadjuvant Endocrine Therapy Showcases Testing Capabilities in Breast Cancer

October 6th 2019

In breast cancer, neoadjuvant endocrine therapy shows promise in a variety of areas, including as an excellent testing platform, Ingrid A. Mayer, MD, MSCI, said in a presentation during the 2019 Lynn Sage Breast Cancer Symposium.

Trends in Pathologic Complete Response After Neoadjuvant Chemo in Breast Cancer

October 5th 2019

In contemporary breast cancer clinical practice, the correlation between achieving a pathologic complete response after neoadjuvant chemotherapy and significantly improved outcomes after chemotherapy has been well established. However, in a discussion at the 2019 Lynn Sage Breast Cancer Symposium, William J. Gradishar, MD, cautioned colleagues that there is more to the story when one looks at long-term data in these patients.

Dr. Morrow on Patient Selection for Nipple Sparing Mastectomy

October 5th 2019

Monica Morrow, MD, discusses the factors that impact the decision to use nipple sparing mastectomy versus conventional mastectomy in patients with breast cancer. The decision to use a nipple sparing approach in patients is dependent on 2 considerations. These relate to the cancer as well as cosmetic appearance of the breast.

Inflammatory Breast Cancer Has Diagnostic Challenges, Requires More Awareness

October 5th 2019

Naoto Tada Ueno, MD, PhD, FACP, discusses the diagnosis and treatment of patients with inflammatory breast cancer and highlights the biggest challenges in both diagnosing and treating this patient population.

Dr. King on Neoadjuvant Chemotherapy in Breast Cancer

October 5th 2019

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Womens Cancer Center, discusses the role of a multidisciplinary team when considering neoadjuvant chemotherapy (NAC) for patients with breast cancer.

Patient Selection Key When De-Escalating Radiation in Breast Cancer

October 5th 2019

Jonathan B. Strauss, MD, MBA, discussed the role of hypofractionated radiotherapy in patients with breast cancer and offered advice on treatment selection.

Multipronged De-Escalated Chemo Strategy Could Yield Best Results in HER2+ Breast Cancer

October 5th 2019

As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.

Dr. Ganz on the Symptoms Related to Estrogen in Breast Cancer

October 5th 2019

Patricia Ganz, MD, discusses the symptoms related to estrogen hormones that can cause more implications for women with breast cancer, including menopausal symptoms such as hot flashes, vaginal dryness, trouble sleeping, and fatigue.

Updated HER2+ Breast Cancer Guidelines Offer Additional Insight, But Questions Remain

October 4th 2019

Clinical guidelines have been necessary to help oncologists stay current in the face of rapidly evolving knowledge in HER2-positive breast cancer.

Dr. Van Zee on Prevention of Invasive Recurrence in Breast Cancer

October 4th 2019

Kimberly Van Zee, MD, discusses the importance of preventing invasive recurrence in patients with breast cancer at the 21st Annual Lynn Sage Breast Cancer Symposium.

Dr. Cristofanilli Discusses Roles of a Multidisciplinary Team in Breast Cancer

October 14th 2018

Massimo Cristofanilli, MD, discusses a session at the 20th Annual Lynn Sage Breast Cancer Symposium on the roles of a multidisciplinary team.

Dr. Sledge on Genomic Sequencing in Patients With Breast Cancer

October 14th 2018

George Sledge, Jr., MD, discusses the benefit to the cost of genomic sequencing decreasing overtime.

Molecular Profiling in Metastatic Breast Cancer: Not Yet Standard of Care, But May Be in Near Future

October 14th 2018

As the cost of sequencing continues to fall, genomic testing will likely become widespread in all types of metastatic cancer, including breast cancer.

Gradishar Addresses 20 Years of Breast Cancer Advancements

October 14th 2018

William J. Gradishar, MD, discusses how far the breast cancer field has advanced over the last 20 years and the data he is anticipating to read out in the future.

Predictive Value Examined Among Genomic Tests for Breast Cancer

October 14th 2018

Multiple gene signature assays have been developed that supply prognostic information for decisions on adjuvant chemotherapy and whether therapy should be of extended duration.